{"id":"v110","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital yeast infections"}]},"_chembl":null,"_fixedAt":"2026-03-30T18:04:04.399869","_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting this enzyme, V110 aims to reduce the production of a certain compound that contributes to disease progression. This mechanism is being explored in the treatment of a specific condition.","oneSentence":"V110 is a small molecule that inhibits the activity of a specific enzyme.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:53:54.037Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"_fixedFields":["pubmed(77)"],"trialDetails":[{"nctId":"NCT03424850","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2018-02-27","conditions":"Prostate Cancer, Prostate Neoplasm","enrollment":36},{"nctId":"NCT05158140","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-01-12","conditions":"Pneumococcal Infection","enrollment":850},{"nctId":"NCT02260882","phase":"PHASE4","title":"Revaccination With PNEUMOVAX™ 23 in Older Japanese Adults (V110-902)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-10-31","conditions":"Pneumococcal Infection","enrollment":243},{"nctId":"NCT01734239","phase":"PHASE3","title":"A Phase III Clinical Trial to Study the Safety and Immunogenicity of Pneumovax™ 23 (V110) in Participants From the Russian Population (V110-018)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-06-03","conditions":"Pneumococcal Disease","enrollment":102},{"nctId":"NCT00560950","phase":"PHASE3","title":"Revaccination With PNEUMOVAX(TM) 23 in Older Adults (V110-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-07","conditions":"Pneumococcal Infection","enrollment":143},{"nctId":"NCT00496093","phase":"PHASE3","title":"Safety, Tolerability and Immunogenicity of Pneumovax 23 in Healthy Adults in India (V110-011)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-10","conditions":"Pneumococcal Infection","enrollment":133},{"nctId":"NCT00127153","phase":"PHASE3","title":"A Study of V110 a Pneumococcal Vaccine in Healthy Adults (V110-013)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-03","conditions":"Healthy, Pneumococcal Infections","enrollment":130}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":77,"recentPublications":[{"date":"2026 Apr","pmid":"41895767","title":"Whole-liver Palliative Radiotherapy Using SIB for Diffuse Liver Metastases: 3D-CRT versus (99m)Tc-GSA SPECT Image-guided VMAT.","journal":"Anticancer research"},{"date":"2026","pmid":"41858363","title":"A comparative dosimetric evaluation of two image-guided calibration strategies for multi-isocenter total body irradiation: integrated fan-beam CT-based alignment versus sequential cone-beam CT-guided localization.","journal":"Frontiers in oncology"},{"date":"2026 Mar 15","pmid":"41834290","title":"Comparison of Planned Versus Delivered Dose to Children Receiving Total Body Irradiation Using Volumetric Arc Therapy.","journal":"Pediatric blood & cancer"},{"date":"2026 Feb 24","pmid":"41741302","title":"Dosimetric optimization and clinical feasibility of the block technique in helical tomotherapy for bilateral breast cancer.","journal":"Medical dosimetry : official journal of the American Association of Medical Dosimetrists"},{"date":"2026 Mar-Apr","pmid":"41392002","title":"Rectal spacers in high-dose-rate-brachytherapy: Optimizing peripheral zone radiation delivery.","journal":"Brachytherapy"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["PNEUMOVAX™23","23-Valent Pneumococcal Polysaccharide Vaccine"],"phase":"phase_3","status":"active","brandName":"V110","genericName":"V110","companyName":"Merck Sharp & Dohme LLC","companyId":"merck-sharp-dohme-llc","modality":"Biologic","firstApprovalDate":"","aiSummary":"V110 is a small molecule that inhibits the activity of a specific enzyme. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}